Zopolrestat

This classification denotes an aldose reductase inhibitor with the molecular formula C19H12F3N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1PV3S9WP3D, chemically known as 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid but generally known as zopolrestat, which bears US NIH Compound Identifier 1613. European Medicines Agency schedules Zopolrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00189MIG. The term ZOPOLRESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). ZOPOLRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zopolrestat under HS 29341000 and SITC 51579. As of Q4 2014, ZOPOLRESTAT remains the US FDA Preferred Term for this commodity. Zopolrestat bears US NLM identifiers UMLS ID C0085066 and NCI Concept Code C82174. SMILES: S1C(NC2C1CCC(C2)C(F)(F)F)CN1NC(C2C(C1=O)CCCC2)CC(=O)O.